

Manuscript Information

Journal name: Journal of sleep research
NIHMS ID: NIHMS859541
Manuscript Title: Impact of continuous positive airway pressure (CPAP) on quality of life in patients with obstructive sleep apnea (OSA)
Submitter: Stuart F.. Quan (Stuart_Quan@hms.harvard.edu)

Manuscript Files

Type	Fig/Table #	Filename	Size	Uploaded
manuscript		Final Manuscript for PubMed Central.pdf	522775	2017-03-12 22:20:12

This PDF receipt will only be used as the basis for generating PubMed Central (PMC) documents. PMC documents will be made available for review after conversion. Any corrections that need to be made will be done at that time. No materials will be released to PMC without the approval of an author. Only the PMC documents will appear on PubMed Central -- this PDF Receipt will not appear on PubMed Central.

1
2
3 **IMPACT OF CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) ON QUALITY OF LIFE IN**
4
5 **PATIENTS WITH OBSTRUCTIVE SLEEP APNEA (OSA)**
6
7
8

9
10 Salma Batool-Anwar, M.D., M.P.H. ¹

11 James L. Goodwin, Ph.D. ²

12 Clete A. Kushida MD., Ph.D,³

13 James A. Walsh, PhD⁴

14 Richard D. Simon, M.D. ⁵

15 Deborah A. Nichols. M,S,³

16 Stuart F. Quan, M.D. ^{1,2}

17
18
19
20
21
22
23
24
25
26
27 ¹Division of Sleep and Circadian Disorders Medicine, Brigham and Women's Hospital and
28 Division of Sleep Medicine, Harvard Medical School, Boston, MA, ²Arizona Respiratory Center,
29 University of Arizona College of Medicine, Tucson, AZ, ³Stanford University, Stanford CA, ⁴ St
30 Luke's Hospital, Chesterfield, MO, ⁵St. Mary Medical Center, Walla Walla, WA
31
32
33
34
35
36
37

38 Running Head: Quality of Life after CPAP

39 Total number of words; 5273, number of references: 37, number of Tables: 4
40
41
42
43

44 Correspondent:

45 Salma Batool-Anwar, M.D., M.P.H.

46 Division of Sleep and Circadian Disorders, Brigham and Women's Hospital

47 221 Longwood Ave.

48 Boston, MA 02115

49 Email: sbatool@bics.bwh.harvard.edu
50
51
52
53
54
55
56
57
58
59
60

Author Contributions

Salma Batool-Anwar, Stuart F. Quan

Drafting/revising the manuscript for content, including medical writing for content

Study concept or design

Analysis or interpretation of data

Clete A. Kushida, James A. Walsh, James L. Goodwin, Richard D. Simon, Deborah A.

Nichols

Study concept or design

Drafting/revising the manuscript for content, including medical writing for content

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Summary

Obstructive Sleep Apnea is a chronic illness with increasing prevalence. In addition to associated cardiovascular comorbidities, obstructive sleep apnea syndrome has been linked to poor quality life, occupational accidents, and motor vehicle crashes secondary to excessive daytime sleepiness. Although continuous positive airway pressure is the gold standard for sleep apnea treatment, its effects on quality of life are not well defined. In the current study we investigated the effects of treatment on quality of life using the data from a subset of the Apnea Positive Pressure Long-term Efficacy Study (APPLES), a randomized controlled trial of continuous positive airway pressure (CPAP) vs. sham CPAP. The Calgary Sleep Apnea Quality of Life Index (SAQLI) was used to assess quality of life. We found that long-term improvement in quality of life occurs with the use of CPAP in persons with severe and possibly moderate sleep apnea. However no demonstrable improvement in quality of life was noted among participants with mild obstructive sleep apnea.

Keywords: Continuous positive airway pressure, sleep apnea quality of life, daytime sleepiness, obstructive sleep apnea

Background

1
2
3 Interest in quality of life (QoL) measures for chronic diseases has increased in recent years. In the United
4
5 States, the Healthy People 2020 initiative identified QoL improvement across all life stages as a central
6
7 public health goal(Sondik et al.). Obstructive sleep apnea (OSA) syndrome is one of the chronic illnesses
8
9 specifically targeted, with an estimated prevalence in the range of 2-5% to 3-7% among women and men
10
11 respectively(Punjabi, 2008, Punjabi et al., 2009). In addition to its strong association with cardiovascular
12
13 co-morbidities and an increased risk for motor vehicle crashes(Terán-Santos et al., 1999), several
14
15 studies have reported an association between OSA and poor QoL(Yang et al., 2000). Moreover, the
16
17 main reasons patients seek medical attention are daytime sleepiness, fatigue, and social or emotional
18
19 difficulties, all of which are likely to negatively affect quality of life.
20
21
22
23

24
25 Continuous positive airway pressure (CPAP) is the most efficacious and commonly used treatment for
26
27 patients with OSA(Task Force of the American Academy of Sleep Medicine, 2009). It has been shown to
28
29 improve daytime sleepiness, reduce blood pressure, and ameliorate cardiovascular risk(Durán-Cantolla
30
31 et al., Becker et al., 2003, Kribbs et al., 1993). Some studies have demonstrated a dose response
32
33 relationship with greater benefit accruing with increased nightly use although the amount of improvement
34
35 is relatively less for usage exceeding 4 hours(Sawyer et al.). Although improvement in QoL with CPAP
36
37 therapy has been demonstrated(Engleman et al., 1997), whether this benefit is maintained over an
38
39 extended period of time remains to be determined. Furthermore, it is unclear if the impact of CPAP on
40
41 QoL is limited to only those with the more severe manifestations of this condition or if there are benefits
42
43 to those with mild OSA as well. Results of the few studies that have addressed this issue have been
44
45 discordant(Engleman et al., 1999, Barnes et al., 2004, Akashiba et al., 2002, Baldwin et al., 2001, Gall et
46
47 al., 1993).
48
49
50
51

52
53 The Calgary Sleep Apnea Quality of Life Index (SAQLI) was developed as a sleep apnea-specific quality
54
55 of life instrument responsive to changes in treatment(Ward Flemons and Reimer, 1998) . It has been
56
57 shown to have high internal consistency and reliability, and construct validity as shown by its positive
58
59 correlation with the more generic Medical Outcomes Survey Short Form-36 (SF-36). SAQLI items are
60

Quality of Life After CPAP

2
2

1
2
3
4
5 organized into domains assessing daily functioning, social interactions, emotional functioning, symptoms
6
7 potentially related to OSA, and treatment-related symptoms(Flemons and Reimer, 2002). Research
8
9 suggests that the SAQLI measures components of health-related QoL important to sleep apnea patients
10
11 and can be used to measure within patient change following treatment intervention.
12
13
14

15 The objective of this investigation was to extend the results of previous studies and determine whether
16
17 the effects of CPAP on QoL are maintained over a prolonged period of time using a sleep apnea specific
18
19 QoL instrument. An additional goal was to assess whether there are benefits across the entire spectrum
20
21 of OSA severity. The analysis was conducted using the data from a subset of the Apnea Positive
22
23 Pressure Long-term Efficacy Study (APPLES), a randomized controlled trial of CPAP vs. Sham CPAP
24
25 over 6 months(Kushida et al., 2006) We hypothesized that treatment with CPAP would be associated
26
27 with improvement in overall QoL as assessed by the SAQLI and that the association would be mediated
28
29 by baseline OSA severity.
30
31
32
33

34 35 **Methods**

36 37 Study Population and Protocol

38
39
40
41 APPLES was a 6-month multicenter, randomized, double-blinded, 2-arm, sham-controlled, intention-to-
42
43 treat study of CPAP efficacy on three domains of neurocognitive function in OSA. A detailed description
44
45 of the protocol has previously been published(Kushida et al., 2006) . Briefly, the participants were either
46
47 recruited through local advertisement or from those attending sleep clinics for evaluation of possible
48
49 OSA. The initial clinical evaluation included administering informed consent, screening questionnaires, a
50
51 history and physical examination, and a medical assessment by a study physician. Participants
52
53 subsequently returned 2-4 weeks later for a 24-h sleep laboratory visit, during which polysomnography
54
55 (PSG) was performed to confirm the diagnosis, followed by a day of neurocognitive, mood, sleepiness,
56
57 and QoL testing.
58
59
60

1 Quality of Life After CPAP

3
3

2
3
4
5 Inclusion and exclusion criteria have been published previously and included age ≥ 18 years and a
6
7 clinical diagnosis of OSA, as defined by American Academy of Sleep Medicine (AASM) criteria and an
8
9 apnea hypopnea index (AHI) ≥ 10 by PSG. Exclusion criteria included: previous treatment for OSA with
10
11 CPAP or surgery, oxygen saturation on baseline PSG $<75\%$ for $>10\%$ of the recording time, history of
12
13 motor vehicle accident related to sleepiness within the past 12 months, presence of chronic medical
14
15 conditions, use of various medications known to affect sleep or neurocognitive function, and various
16
17 health and social factors that may impact standardized testing procedures (e.g., shift work).
18
19

20
21
22 Following the PSG, participants with an AHI ≥ 10 who met other enrollment criteria were randomized to
23
24 CPAP or sham CPAP for continued participation in APPLES. After randomization, participants returned
25
26 to the sleep laboratory for a CPAP or sham CPAP titration PSG. Subsequent assessments were made at
27
28 2, and 6 months post-randomization at which time a test battery was re-administered including QoL
29
30 questionnaires.
31
32

33 34 Assessment of Quality of Life

35
36
37
38 *Calgary Sleep Apnea Quality of Life Index (SAQLI)*: The SAQLI was developed as a sleep apnea-specific
39
40 QoL instrument that assesses components deemed important to patients (Ward Flemons and Reimer,
41
42 1998). It was designed as an interview administered by trained staff. The first 35 items capture
43
44 responses assessing daily functioning, social interactions, and emotional functioning. Next, symptoms
45
46 are reviewed that may be experienced by patients with sleep apnea, and participants are asked to select
47
48 up to five symptoms they consider the most important for evaluation. Once treatment has been initiated,
49
50 five treatment-related symptoms are also selected and evaluated. Items are scored on a 7-point scale
51
52 where the wording varies slightly depending on the question; examples of the most extreme responses
53
54 are “all of the time” and “not at all.” Item and domain scores are averaged, taking into account the impact
55
56
57
58
59
60

1 Quality of Life After CPAP

4
4

2
3
4
5 of treatment-related symptoms, to yield a composite total score between 1 and 7. Higher scores
6
7 represent better QoL.

8
9
10
11 Assessments of Mood and Sleepiness

12
13
14
15 *Beck Depression Inventory II (BDI)*: The BDI is a validated 21-question multiple choice self-reported
16
17 inventory, and is one of the most widely used instruments for measuring the severity of depression (Beck
18
19 and Steer, 1987). Items are scored on a 4-point severity scale, where a higher BDI total score suggests a
20
21 higher level of depression. A score of 14 or above is consistent with at least mild depression.
22
23

24
25 *The Profile of Mood States (POMS)*: The POMS is an established measure of transient mood states with
26
27 high reliability and validity. The scale consists of 65 self-rated adjectives on a 5-point scale with the
28
29 instruction to rate each item "at the present time" (McNair et al.). Possible responses are: not at all, a
30
31 little, moderately, quite a lot, or extremely. Six mood states are measured in the POMS: tension-anxiety,
32
33 depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment. These
34
35 factors can be combined to form the POMS total mood disturbance (TMD) score. Higher scores
36
37 represent more negative mood states.
38
39
40
41
42
43

44 *Hamilton Rating Scale for Depression (HMD)*: The HMD is a validated 21-item clinician-administered
45
46 assessment of the severity of depression. APPLS used a modified version of this test administered by
47
48 trained staff. In this psychometrician-administered interview, 17 questions (e.g., depressed mood,
49
50 suicide, work and anhedonia, retardation, agitation, gastrointestinal or general somatic symptoms,
51
52 hypochondriasis, loss of insight or weight) were asked to identify and monitor depressive
53
54 symptomatology. Interviews were scored using either a 3- or 5-point scale based on intensity and
55
56 frequency, and were summed to provide a single total score (Hamilton, 1960).
57
58
59
60

Quality of Life After CPAP

5
5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Epworth Sleepiness Scale (ESS): The ESS is a validated 8-item questionnaire designed to measure subjective sleepiness. It was originally designed to distinguish normal patients from those with sleep disorders such as OSA and narcolepsy (Johns, 1991). This self-administered instrument rates how likely a patient is to doze off or fall asleep during certain situations (*i.e.*, no chance of dozing, slight chance of dozing, moderate chance of dozing, high chance of dozing), and averages the responses to derive a total score. Higher scores represent a higher level of subjective sleepiness.

Polysomnography

The PSG montage included monitoring of the electroencephalogram (EEG, C₃-A₂ or C₄-A₁, O₂-A₁ or O₁-A₂), electrooculogram (EOG, ROC-A₁, LOC-A₂), chin and anterior tibialis electromyograms (EMG), heart rate by 2-lead electrocardiogram, snoring intensity (anterior neck microphone), nasal pressure (nasal cannula), nasal/oral thermistor, thoracic and abdominal movement (inductance plethysmography bands), and oxygen saturation (pulse oximetry). All PSG records were electronically transmitted to a centralized data coordinating and PSG reading center. Sleep and wakefulness were scored using Rechtschaffen and Kales criteria (Rechtschaffen and Kales, 1968). Apneas and hypopneas were scored using American Academy of Sleep Medicine Task Force (1999) diagnostic criteria (Flemons et al., 1999). Briefly, an apnea was defined by a clear decrease (> 90%) from baseline in the amplitude of the nasal pressure or thermistor signal lasting ≥ 10 sec. Hypopneas were identified if there was a clear decrease (> 50% but $\leq 90\%$) from baseline in the amplitude of the nasal pressure or thermistor signal, or if there was a clear amplitude reduction of the nasal pressure signal ≥ 10 sec that did not reach the above criterion, but was associated with either an oxygen desaturation > 3% or an arousal. Obstructive events were scored if there was persistence of chest or abdominal respiratory effort. Central events were noted if no displacement occurred on either the chest or abdominal channels. Sleep apnea was classified as mild (AHI 10.0 to 15.0 events per hour), moderate (AHI 15.1 to 30.0 events per hour), and severe (AHI more than 30 events per hour) (Flemons et al., 1999)

1 Quality of Life After CPAP

6
6

2
3
4
5 Statistical Analysis

6
7
8 Univariate and multivariate logistic regression models were used to estimate the degree to which
9 variables correlated with QoL scores. We examined the association between the SAQLI and the
10 following variables: OSA severity as measured by the AHI, sleepiness as assessed by ESS, age,
11 baseline body mass index (BMI, kg/m²), and mood measured by HMD, POMS, and BDI. PSG sleep
12 efficiency and total sleep time were included in the models if significant correlations were observed on
13 univariate analysis.
14
15

16
17
18 A paired sample t-test was conducted to compare effects of treatment (CPAP vs. Sham CPAP) on
19 SAQLI at 2 and 6 months. To assess factors associated with the minimum clinically relevant
20 improvement in SAQLI total score (>1.0) (Flemons and Reimer, 2002), binary logistic regression models
21 were constructed. For these models, dichotomous variables were created for treatment (CPAP vs.
22 SHAM), OSA severity (AHI < 15 vs. ≥ 15), obesity (BMI <30 kg/m² vs. ≥30 kg/m²), depression (BDI <14
23 vs. ≥14), CPAP compliance (< 4 hours/night vs. ≥4 hours/night), and excessive sleepiness (ESS <10 vs.
24 ≥10).
25
26

27
28
29 Finally we used unpaired t-tests to assess the effect of gender and OSA severity on change in ESS total
30 score in both the CPAP and Sham CPAP groups. Data for continuous and interval variables were
31 expressed as mean ± SD, and as a percentage for categorical variables. Statistical significance was set
32 at a *P* value <0.05, two-tailed. Analyses were performed using STATA (Version 11, StataCorp TX USA).
33
34
35
36
37
38
39

40
41
42 **Results**

43
44
45 Table 1 includes demographic and baseline outcome measure values for the CPAP and Sham groups
46 (n=443 and 402 respectively) with SAQLI data. The two groups were generally similar in mean age, sex
47 ratio, proportion of white participants and average BMI. Similar proportions of the two groups had severe
48 OSA (57%), with an average AHI of 40 /hour. The average CPAP adherence at 2 and 6 months was 3.43
49
50
51
52
53
54
55
56
57
58
59
60

1 Quality of Life After CPAP

7
7

2
3
4
5 ± 2.8 and 2.92 ± 2.9 hours/night for the Sham group vs. 4.31 ± 2.9 and 3.69 ± 3.1 hours per night in the
6 CPAP group. BDI scores in both groups averaged approximately 6. Interestingly, the participants in the
7 CPAP arm reported higher baseline POMS scores. The participants in both randomized groups had
8 similar SAQLI scores at baseline. At the 2 and 6 month visits (data not shown) no significant change was
9 noted in total sleep time and sleep efficiency. However, a significant decrease in arousal index was noted
10 at 6 months in the CPAP group (29/hour vs. 16/hour $P < 0.001$). There was also a trend for the CPAP
11 group to have a lower POMS score at 6 months, however the results were not statistically significant (12
13 vs. 6.6, $P = 0.07$).

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
To assess QoL between treatment arms over time, we compared overall SAQLI total score at the three
study visits and found no significant differences in means (Table 2a and Table 2b). Analyses were also
stratified by OSA severity (mild, moderate, and severe), but no significant differences were detected.
Additional focused analyses indicated a significant decline in SAQLI at 2 months among participants with
mild OSA (4.6 to 4.2, $p = 0.04$). This decline in SAQLI primarily occurred among participants with less than
4-hour use of CPAP. In contrast compared to Sham CPAP, participants in the CPAP arm with severe
OSA and CPAP usage > 4 hours/night had a small, but significant improvement in their SAQLI scores
(4.7 to 5.0, $P < 0.05$) at 6 months (Table 2b).

A multivariate logistic regression analysis was performed to identify factors predicting a change in the
SAQLI of at least 1 total score (Table 3). Compared to the Sham CPAP arm, the participants in CPAP
arm demonstrated increased odds of having a change in SAQLI total score of at least 1 (OR: 1.66, 95%
CI: 1.1-2.6, $P < 0.03$). Of note, severity of OSA (moderate to severe vs. mild) and CPAP compliance were
not predictive of SAQLI change. Similarly, a one unit change in ESS total score also predicted significant
change in SAQLI total score of at least 1 (OR: 1.76, 95% CI: 1.1-2.7, $P < 0.01$).

1 Quality of Life After CPAP

8
8

2
3
4
5 Finally, as shown in Table 4, compared to the SHAM group significant improvement in ESS was noted
6
7 amongst the CPAP group ($P < 0.05$) for participants with moderate or severe OSA and the results were
8
9 more prominent among women. No significant change in ESS was noted in mild OSA group in either
10
11 treatment arm.
12

13 Discussion

14
15
16
17 Our results demonstrate that CPAP use of ≥ 4 hours per night among patients with severe OSA improves
18
19 QoL as measured by the SAQLI. Clinically important changes in QoL occurred primarily in those who
20
21 were subjectively sleepy. Our findings emphasize the importance of treatment adherence in predicting
22
23 QoL improvements in patients with OSA. These results are in accordance with previous studies
24
25 underscoring the importance of CPAP compliance. Using the functional outcomes of sleep questionnaire
26
27 (FOSQ) as the QoL measure, Weaver *et al.* demonstrated improvement in FOSQ total score after CPAP
28
29 use. Almost 67% of participants with CPAP, use of more than 5 hours achieved a score of 17.9 or above.
30
31 In contrast, only 33% of participants with CPAP use of less than 2 hours had similar improvement in
32
33 QoL (Weaver *et al.*, 2007). Likewise, a large retrospective study of the French population using the
34
35 Nottingham Health Profile (NHP) demonstrated that OSA patients with intermediate CPAP compliance
36
37 (4-7 hours/night) had a better perception of their health than the poorly compliant patients (< 4
38
39 hours/night) (Meslier *et al.*, 1998). In another small study of 29 patients, 8 weeks of CPAP therapy ($6.0 \pm$
40
41 1.6 hours/night) demonstrated significant improvement in vitality, social functioning, and mental health (p
42
43 < 0.05) compared to baseline values (D'Ambrosio *et al.*, 1999). Similarly a meta-analysis ($n = 1256$) found
44
45 improvement in physical function, energy/vitality, and the physical component summary (PCS) domain of
46
47 the SF-36 after CPAP use (Jing *et al.*, 2008). However, QoL was not measured among the non-compliant
48
49 patients in these studies. Thus, there is limited research on the effect of CPAP on QoL in randomized
50
51 controlled trials, and our study is one such study demonstrating improvement in the SAQLI after CPAP
52
53 use.
54
55
56
57
58
59
60

Quality of Life After CPAP

9
9

1
2
3
4
5 The current study also indicates increased odds of a SAQLI total score change of >1.0 for participants
6
7 with moderate to severe OSA and those adhering to CPAP (≥ 4 hours /night). It has been suggested that
8
9 the minimal important difference in SAQLI score is approximately 1, and a score of this magnitude is
10
11 associated with a clinically meaningful improvement in QoL for patients with sleep apnea (Flemons and
12
13 Reimer, 2002). Our findings indicate that in addition to those with severe OSA, patients with moderately
14
15 severe OSA also may experience some improvement in QoL with CPAP.
16
17

18
19
20 Impairment in physical health domains of health-related QoL has been reported among patients with
21
22 OSA (Lacasse et al., 2002). Although CPAP treatment leads to improvement, very few studies have
23
24 shown correlation between OSA severity and the QoL measures (Avlonitou et al., Engleman et al., 1997,
25
26 Barnes et al., 2002, Tousignant et al., 1994, Sanner et al., 2000). In a retrospective study of 19
27
28 participants, positive correlation was demonstrated between OSA severity and health state (Tousignant et
29
30 al., 1994). Similarly, in another study examining the long term effects of CPAP, a very weak correlation
31
32 was observed between mean oxygen saturation at night and QoL as measured by the complaint
33
34 list (Sanner et al., 2000). In contrast, for our study, severity of OSA played a vital role in predicting change
35
36 in SAQLI total score for those randomized to the therapeutic CPAP treatment arm. Participants in the
37
38 CPAP arm with severe OSA demonstrated improvement in SAQLI total score. No significant change in
39
40 SAQLI was noted for participants with mild OSA.
41
42
43
44
45

46
47 In contradistinction to our results, others have reported improvement in QoL independent of OSA
48
49 severity. Avlonitou *et al.* demonstrated significant improvement in SAQLI scores after CPAP treatment in
50
51 the domains of social interactions and daily and emotional functioning irrespective of OSA
52
53 severity (Avlonitou et al.). Prior to CPAP treatment, patients in the study by Avionitou *et al.* ($n=50$)
54
55 reported a higher ESS total score, and the symptoms that showed the greatest improvement were those
56
57 associated with daytime sleepiness. Similarly, significant increases in SF-36 scores after CPAP therapy
58
59 has been reported in patients with mild sleep apnea with severely impaired QoL measures (Engleman et
60

Quality of Life After CPAP

10

10

1
2
3
4
5 al., 1997, D'Ambrosio et al., 1999). Excessive sleepiness, not the severity of OSA, was thought to be
6
7 responsible for low QoL scores in these studies. Our finding of an association between a change in
8
9 SAQLI >1 and sleepiness is consistent with these previous studies and emphasizes the importance of
10
11 sleepiness in determining QoL in patients with OSA.
12
13

14
15 Daytime sleepiness is one of the main reasons patient seek medical attention, and commonly, subjective
16
17 sleepiness is assessed using the ESS. Although subjective sleepiness as measured by the ESS
18
19 improved in both groups, the change in ESS total score was significantly greater for participants
20
21 randomized to the CPAP treatment arm and was predominantly seen among patients with moderate to
22
23 severe OSA. Thus, our data provide additional evidence that CPAP is an effective treatment for OSA-
24
25 related sleepiness over the long-term.
26
27

28
29 Quality of life is becoming an increasingly important construct in evaluating the benefits of treatment for
30
31 many conditions. With respect to OSA, QoL has been selected as a quality metric to evaluate the
32
33 standard of care rendered to patients(Aurora et al.). Research suggests that QoL among patients with
34
35 OSA is not only limited to daytime sleepiness, but rather encompasses a wider perception of
36
37 performance in domains such as physical function, emotional state, and social interaction. The SAQLI
38
39 was developed to identify symptoms more relevant to patients, and thus should be an appropriate tool to
40
41 measure treatment success in those with OSA. Our data demonstrating that the SAQLI is responsive to
42
43 CPAP intervention supports its use in this context.
44
45
46
47

48
49 While our initial overall comparisons of total SAQLI score by treatment arm across study visits
50
51 demonstrate a significant decrease in SAQLI scores in the mild OSA group who were treated with Sham
52
53 CPAP, we found that long-term improvement in QoL occurs with the use of CPAP in persons with OSA
54
55 who have severe, and possibly moderate OSA, and who are moderately compliant with CPAP. The
56
57
58
59
60

1 Quality of Life After CPAP

11

11

2
3
4
5 decline in SAQLI in participants with mild OSA could be explained by the fact that the mild OSA patients
6
7 with minimal symptoms found Sham CPAP to be uncomfortable as reflected in SAQLI score.
8
9

10 Strengths of this study include a large number of participants across multiple sites, randomized CPAP
11 and Sham CPAP control groups, documentation of CPAP compliance at 6 months, and adjustment for
12 multiple confounders that can affect QoL. Despite its strengths, the current study has some limitations.
13
14 First, since the study was randomized to groups (CPAP and Sham CPAP) with no control arm, the
15 possibility of placebo effect cannot be excluded even in the Sham CPAP arm. Second, the change in
16 QoL after 6 months of CPAP treatment does not necessarily predict maintenance of this long-term
17 clinical improvement indefinitely. Third, participants with very severe OSA were excluded from this study
18 based on the exclusion criteria related to low oxygen saturation (saturation on baseline PSG <75% for
19 >10% of the recording time). Lastly, our results are not necessarily applicable to other treatment
20 modalities for OSA, such as oral appliances or upper airway surgery.
21
22
23
24
25
26
27
28
29
30
31
32

33
34 In conclusion, the findings of this study demonstrate that QoL improves in patients with severe and
35 possibly moderate OSA who are adequately treated with CPAP, and this improvement is maintained over
36 an extended time period. Future studies are needed with longer follow-up on OSA patients, treated with
37 more diverse treatment modalities, with and without subjective sleepiness, to more thoroughly assess
38 long-term effects of OSA treatment on overall QoL.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Quality of Life After CPAP

12

12

2
3
4
5 **Acknowledgements**

6
7
8 APPLES was funded by contract 5UO1-HL-068060 from the National Heart, Lung and Blood Institute.

9
10 The APPLES pilot studies were supported by grants from the American Academy of Sleep Medicine and
11 the Sleep Medicine Education and Research Foundation to Stanford University and by the National
12 Institute of Neurological Disorders and Stroke (N44-NS-002394) to SAM Technology. In addition,
13 APPLES investigators gratefully recognize the vital input and support of Dr. Sylvan Green who died
14 before the results of this trial were analyzed, but was instrumental in its design and conduct.
15
16
17
18
19
20
21
22

23 **Administrative Core**

24
25 Clete A. Kushida, MD, PhD; Deborah A. Nichols, MS; Eileen B. Leary, BA, RPSGT; Pamela R. Hyde,
26 MA; Tyson H. Holmes, PhD; Daniel A. Bloch, PhD; William C. Dement, MD, PhD
27
28
29
30

31 **Data Coordinating Center**

32
33 Daniel A. Bloch, PhD; Tyson H. Holmes, PhD; Deborah A. Nichols, MS; Rik Jadrnicek, Microflow, Ric
34 Miller, Microflow Usman Aijaz, MS; Aamir Farooq, PhD; Darryl Thomander, PhD; Chia-Yu Cardell,
35 RPSGT; Emily Kees, Michael E. Sorel, MPH; Oscar Carrillo, RPSGT; Tami Crabtree, MS; Booil Jo, PhD;
36 Ray Balise, PhD; Tracy Kuo, PhD
37
38
39
40
41
42

43 **Clinical Coordinating Center**

44
45 Clete A. Kushida, MD, PhD, William C. Dement, MD, PhD, Pamela R. Hyde, MA, Rhonda M. Wong, BA,
46 Pete Silva, Max Hirshkowitz, PhD, Alan Gevins, DSc, Gary Kay, PhD, Linda K. McEvoy, PhD, Cynthia S.
47 Chan, BS, Sylvan Green, MD
48
49
50
51
52

53 **Clinical Centers**

54
55
56 *Stanford University*

57
58
59 Christian Guilleminault, MD; Eileen B. Leary, BA, RPSGT; David Claman, MD; Stephen Brooks, MD;
60

1 Quality of Life After CPAP

13

13

2
3
4
5 Julianne Blythe, PA-C, RPSGT; Jennifer Blair, BA; Pam Simi, Ronelle Broussard, BA; Emily Greenberg,
6
7 MPH; Bethany Franklin, MS; Amirah Khouzam, MA; Sanjana Behari Black, BS, RPSGT; Viola Arias,
8
9 RPSGT; Romelyn Delos Santos, BS; Tara Tanaka, PhD

10
11
12 *University of Arizona*

13
14
15 Stuart F. Quan, MD; James L. Goodwin, PhD; Wei Shen, MD; Phillip Eichling, MD; Rohit Budhiraja, MD;
16
17 Charles Wynstra, MBA; Cathy Ward, Colleen Dunn, BS; Terry Smith, BS; Dane Holderman, Michael
18
19 Robinson, BS; Osmara Molina, BS; Aaron Ostrovsky, Jesus Wences, Sean Priefert, Julia Rogers, BS;
20
21 Megan Ruitter, BS; Leslie Crosby, BS, RN

22
23
24
25 *St. Mary Medical Center*

26
27
28 Richard D. Simon Jr., MD; Kevin Hurlburt, RPSGT; Michael Bernstein, MD; Timothy Davidson, MD;
29
30 Jeannine Orock-Takele, RPSGT; Shelly Rubin, MA; Phillip Smith, RPSGT; Erica Roth, RPSGT; Julie
31
32 Flaa, RPSGT; Jennifer Blair, BA; Jennifer Schwartz, BA; Anna Simon, BA; Amber Randall, BA

33
34
35 *St. Luke's Hospital*

36
37
38 James K. Walsh, PhD, Paula K. Schweitzer, PhD, Anup Katyal, MD, Rhody Eisenstein, MD, Stephen
39
40 Feren, MD, Nancy Cline, Dena Robertson, RN, Sheri Compton, RN, Susan Greene, Kara Griffin, MS,
41
42 Janine Hall, PhD

43
44
45 *Brigham and Women's Hospital*

46
47
48 Daniel J. Gottlieb, MD, MPH, David P. White, MD, Denise Clarke, BSc, RPSGT, Kevin Moore, BA, Grace
49
50 Brown, BA, Paige Hardy, MS, Kerry Eudy, PhD, Lawrence Epstein, MD, Sanjay Patel, MD

51
52
53 **Sleep HealthCenters for the use of their clinical facilities to conduct this research*

54
55
56 **Consultant Teams**

57
58
59 *Methodology Team:* Daniel A. Bloch, PhD, Sylvan Green, MD, Tyson H. Holmes, PhD, Maurice M.

1 Quality of Life After CPAP

14

14

2
3
4
5 Ohayon, MD, DSc, David White, MD, Terry Young, PhD

6
7
8 *Sleep-Disordered Breathing Protocol Team:* Christian Guilleminault, MD, Stuart Quan, MD, David White,

9
10 MD

11
12
13 *EEG/Neurocognitive Function Team:* Jed Black, MD, Alan Gevins, DSc, Max Hirshkowitz, PhD, Gary

14
15 Kay, PhD, Tracy Kuo, PhD

16
17
18 *Mood and Sleepiness Assessment Team:* Ruth Benca, MD, PhD, William C. Dement, MD, PhD, Karl

19
20 Doghramji, MD, Tracy Kuo, PhD, James K. Walsh, PhD

21
22
23 *Quality of Life Assessment Team:* W. Ward Flemons, MD, Robert M. Kaplan, PhD

24
25
26 *APPLES Secondary Analysis-Neurocognitive (ASA-NC) Team:* Dean Beebe, PhD, Robert Heaton, PhD,

27
28 Joel Kramer, PsyD, Ronald Lazar, PhD, David Loewenstein, PhD, Frederick Schmitt, PhD

29
30
31 **National Heart, Lung, and Blood Institute (NHLBI)**

32
33
34 Michael J. Twery, PhD, Gail G. Weinmann, MD, Colin O. Wu, PhD

35
36
37 **Data and Safety Monitoring Board (DSMB)**

38
39
40 Seven year term: Richard J. Martin, MD (Chair), David F. Dinges, PhD, Charles F. Emery, PhD, Susan

41
42 M. Harding MD, John M. Lachin, ScD, Phyllis C. Zee, MD, PhD

43
44
45 Other term: Xihong Lin, PhD (2 yrs), Thomas H. Murray, PhD (1 yr)

1 Quality of Life After CPAP 15
2
3
4
5
6
7 15

8 References

- 9 Akashiba, T., Kawahara, S., Akahoshi, T., *et al.* Relationship between quality of life and mood or
10 depression in patients with severe obstructive sleep apnea syndrome*. *Chest*, 2002, 122: 861.
11 Aurora, R. N., Collop, N. A., Jacobowitz, O., Thomas, S. M., Quan, S. F. and Aronsky, A. J. Quality
12 measures for the care of adult patients with obstructive sleep apnea. *J Clin Sleep Med*, 11: 357.
13 Avlonitou, E., Kapsimalis, F., Varouchakis, G., Vardavas, C. and Behrakis, P. Adherence to CPAP
14 therapy improves quality of life and reduces symptoms among obstructive sleep apnea syndrome
15 patients. *Sleep and Breathing*, 16: 563.
16
17 Baldwin, C. M., Griffith, K. A., Nieto, F. J., O'connor, G. T., Walsleben, J. A. and Redline, S. The
18 association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep
19 Heart Health Study. *Sleep*, 2001, 24: 96.
20
21 Barnes, M., Houston, D., Worsnop, C. J., *et al.* A Randomized Controlled Trial of Continuous Positive
22 Airway Pressure in Mild Obstructive Sleep Apnea. *American Journal of Respiratory and Critical
23 Care Medicine*, 2002, 165: 773.
24
25 Barnes, M., Mcevoy, R. D., Banks, S., *et al.* Efficacy of positive airway pressure and oral appliance in
26 mild to moderate obstructive sleep apnea. *American Journal of Respiratory and Critical Care
27 Medicine*, 2004, 170: 656.
28
29 Beck, A. T. and Steer, R. A. Manual for the revised Beck depression inventory. In. San Antonio, TX:
30 Psychological Corporation, 1987.
31
32 Becker, H. F., Jerrentrup, A., Ploch, T., *et al.* Effect of Nasal Continuous Positive Airway Pressure
33 Treatment on Blood Pressure in Patients With Obstructive Sleep Apnea. *Circulation*, 2003, 107:
34 68.
35
36 D'ambrosio, C., Bowman, T. and Mohsenin, V. Quality of life in patients with obstructive sleep apnea*:
37 Effect of nasal continuous positive airway pressure—a prospective study. *Chest*, 1999, 115: 123.
38
39 Durán-Cantolla, J., Aizpuru, F., Montserrat, J. M., *et al.* Continuous positive airway pressure as treatment
40 for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial.
41 *Bmj*, 341
42
43 Engleman, H. M., Kingshott, R. N., Wraith, P. K., Mackay, T. W., Deary, I. J. and Douglas, N. J.
44 Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild
45 sleep apnea/hypopnea syndrome. *American Journal of Respiratory and Critical Care Medicine*,
46 1999, 159: 461.
47
48 Engleman, H. M., Martin, S. E., Deary, I. J. and Douglas, N. J. Effect of CPAP therapy on daytime
49 function in patients with mild sleep apnoea/hypopnoea syndrome. *Thorax*, 1997, 52: 114.
50
51 Flemons, W. W., Buysse, D., Redline, S. and Pack, A. The report of american academy of sleep
52 medicine task force. Sleep related breathing disorders in adults: recommendations for syndrome
53 definition and measurement techniques in clinical research. *Sleep*, 1999, 22: 667.
54
55
56
57
58
59
60

1 Quality of Life After CPAP

16

16

2
3
4
5 Flemons, W. W. and Reimer, M. A. Measurement Properties of the Calgary Sleep Apnea Quality of Life
6 Index. *American Journal of Respiratory and Critical Care Medicine*, 2002, 165: 159.

7
8 Force, A. O. S. A. T. and American Academy of Sleep, M. Clinical guideline for the evaluation,
9 management and long-term care of obstructive sleep apnea in adults. *Journal of clinical sleep*
10 *medicine: JCSM: official publication of the American Academy of Sleep Medicine*, 2009, 5: 263.

11
12 Gall, R., Isaac, L. and Kryger, M. Quality of life in mild obstructive sleep apnea. *Sleep: Journal of Sleep*
13 *Research & Sleep Medicine*, 1993

14
15 Hamilton, M. A rating scale for depression. *Journal of neurology, neurosurgery, and psychiatry*, 1960, 23:
16 56.

17
18 Jing, J., Huang, T., Cui, W. and Shen, H. Effect on quality of life of continuous positive airway pressure in
19 patients with obstructive sleep apnea syndrome: a meta-analysis. *Lung*, 2008, 186: 131.

20
21 Johns, M. W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*,
22 1991, 14: 540.

23
24 Kales, A., Caldwell, A. B., Cadieux, R. J., Vela-Bueno, A., Ruch, L. G. and Mayes, S. D. Severe
25 obstructive sleep apnea—II: Associated psychopathology and psychosocial consequences.
26 *Journal of Chronic Diseases*, 1985, 38: 427.

27
28 Kribbs, N. B., Pack, A. I., Kline, L. R., *et al.* Effects of one night without nasal CPAP treatment on sleep
29 and sleepiness in patients with obstructive sleep apnea. *Am Rev Respir Dis*, 1993, 147: 1162.

30
31 Kushida, C. A., Nichols, D. A., Quan, S. F., *et al.* The apnea positive pressure long-term efficacy study
32 (APPLES): rationale, design, methods, and procedures. *J Clin Sleep Med*, 2006, 2: 288.

33
34 Lacasse, Y., Godbout, C. and Sériès, F. Health-related quality of life in obstructive sleep apnoea.
35 *European Respiratory Journal*, 2002, 19: 499.

36
37 Mcnair, D. M., Lorr, M. and Droppelman, L. F. San Diego, CA: Educational and Industrial Testing
38 Service; 1971. *Manual for the profile of mood states*

39
40 Meslier, N., Lebrun, T., Grillier-Lanoir, V., *et al.* A French survey of 3,225 patients treated with CPAP for
41 obstructive sleep apnoea: benefits, tolerance, compliance and quality of life. *European*
42 *Respiratory Journal*, 1998, 12: 185.

43
44 Punjabi, N. M. The epidemiology of adult obstructive sleep apnea. *Proceedings of the American Thoracic*
45 *Society*, 2008, 5: 136.

46
47 Punjabi, N. M., Caffo, B. S., Goodwin, J. L., *et al.* Sleep-disordered breathing and mortality: a prospective
48 cohort study. *PLoS medicine*, 2009, 6: e1000132.

49
50 Quan, S. F., Gillin, J. C., Littner, M. R. and Shepard, J. W. Sleep-related breathing disorders in adults:
51 Recommendations for syndrome definition and measurement techniques in clinical research.
52 editorials. *Sleep*, 1999, 22: 662.

53
54 Rechtschaffen, A. and Kales, A. A manual of standardized terminology, techniques and scoring system
55 for sleep stages of human subjects. 1968

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Quality of Life After CPAP

17
17

- Sanner, B. M., Klewer, J., Trumm, A., Randerath, W., Kreuzer, I. and Zidek, W. Long-term treatment with continuous positive airway pressure improves quality of life in obstructive sleep apnoea syndrome. *European Respiratory Journal*, 2000, 16: 118.
- Sawyer, A. M., Gooneratne, N. S., Marcus, C. L., Ofer, D., Richards, K. C. and Weaver, T. E. A systematic review of CPAP adherence across age groups: clinical and empiric insights for developing CPAP adherence interventions. *Sleep medicine reviews*, 15: 343.
- Sondik, E. J., Huang, D. T., Klein, R. J. and Satcher, D. Progress toward the healthy people 2010 goals and objectives. *Annual review of public health*, 31: 271.
- Terán-Santos, J., Jimenez-Gomez, A. and Cordero-Guevara, J. The Association between Sleep Apnea and the Risk of Traffic Accidents. *New England Journal of Medicine*, 1999, 340: 847.
- Tousignant, P., Cosio, M. G., Levy, R. D. and Groome, P. A. Quality adjusted life years added by treatment of obstructive sleep apnea. *Sleep: Journal of Sleep Research & Sleep Medicine*, 1994
- Ward Flemons, W. and Reimer, M. A. Development of a Disease-specific Health-related Quality of Life Questionnaire for Sleep Apnea. *American Journal of Respiratory and Critical Care Medicine*, 1998, 158: 494.
- Weaver, T. E., Maislin, G., Dinges, D. F., *et al.* Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. *Sleep*, 2007, 30: 711.
- Yang, E. H., Hla, K. M., Mchorney, C. A., Havighurst, T., Badr, M. S. and Weber, S. Sleep apnea and quality of life. *Sleep*, 2000, 23: 535.

Table 1. Baseline characteristics of APPLES participants with SAQLI data

	All Subjects	After Randomization	
	With SAQLI data	SHAM	CPAP
N	845	402	443
Age, mean year (SD)	52 ± 12	51 ± 12	52 ± 12
Gender, n (% men)	549 (65)	259 (64)	290 (65)
Ethnicity, n, (% White)	644 (76)	304 (76)	340 (77)
BMI (Kg/m ² , SD)	32.2 ± 7.1	32 ± 6.7	32.5 ± 7.5
OSA Severity, n (%)			
Mild	113 (14)	50 (12)	63 (14)
Moderate	249 (29)	121 (30)	128 (29)
Severe	483 (57)	231 (57)	252 (57)
AHI at baseline mean (SD)	40 ± 25	41 ± 25	40 ± 24
ESS mean (SD)	10.4 ± 4.5	10.4 ± 4.4	10.3 ± 4.5
SAQLI at baseline	4.7 ± 0.8	4.7 ± 0.8	4.7 ± 0.8
BDI Score	6.1 ± 4.9	6.3 ± 5.0	5.9 ± 4.9
HMD Score	4.3 ± 4.1	4.1 ± 3.8	4.5 ± 4.3
POMS	8.6 ± 96	5.1 ± 113	11.8 ± 79
Total Sleep Time (min)	376 ± 65	377 ± 63	376 ± 66
Sleep Efficiency (%)	78 ± 13	78.3 ± 12	78 ± 13
Arousal Index	29 ± 20	30 ± 22	29 ± 19
Compliance at 2 Months	3.89 ± 2.9	3.43 ± 2.8	4.31 ± 2.9
Compliance at 6 Months	3.33 ± 3.1	2.92 ± 2.92	3.69 ± 3.1

SD: Standard Deviation, BMI: Body Mass Index, OSA: Obstructive Sleep Apnea, AHI: Apnea Hypopnea Index, ESS: Epworth Sleepiness Scale, BDI: Beck Depression Inventory, HMD: Hamilton Rating Scale for Depression, POMS: Profile of Mood States, SAQLI: Sleep Apnea Quality of Life Index.

Table2a: Change in SAQLI at 2 Months based on treatment groups and OSA severity

	Compliance < 4 hours				Compliance > 4 hours			
	SHAM		CPAP		SHAM		CPAP	
	Baseline	2 M	Baseline	2M	Baseline	2 M	Baseline	2M
<i>N</i>	193	193	157	157	199	199	274	274
OSA	4.6 (0.8)	4.4 (1.3)*	4.6 (0.8)	4.5 (0.8)	4.7 (0.8)	4.7 (1.2)	4.8 (0.8)	4.8 (0.8)
<i>N</i>	25	25	23	23	21	21	38	38
Mild	4.6 (0.6)	4.2 (1.1)*	4.4 (0.8)	4.6 (0.7)	4.9 (0.7)	4.9 (0.7)	4.7 (0.6)	4.6 (0.8)
<i>N</i>	64	64	52	52	55	55	75	75
Moderate	4.7 (0.9)	4.5 (0.9)	4.6 (0.9)	4.3 (0.8)	4.8 (0.7)	4.8 (0.7)	4.8 (0.8)	4.6 (0.8)
<i>N</i>	104	104	82	82	123	123	161	161
Severe	4.6 (0.7)	4.4 (1.6)	4.7 (0.7)	4.6 (0.8)	4.7 (0.8)	4.5 (1.4)	4.9 (0.8)	4.9 (0.7)

Table2b: Change in SAQLI at 6 Months based on treatment groups and OSA severity

	Compliance < 4 hours				Compliance > 4 hours			
	SHAM		CPAP		SHAM		CPAP	
	Baseline	6 M	Baseline	6M	Baseline	6 M	Baseline	6M
<i>N</i>	242	242	193	193	160	160	249	249
OSA	4.6 (0.8)	4.6 (1.0)	4.7 (0.8)	4.7 (0.8)	4.8 (0.8)	4.9 (0.7)	4.7 (0.8)	5.0 (0.7)*
<i>N</i>	34	34	29	29	16	16	34	34
Mild	4.6 (0.7)	4.6 (1.0)	4.5 (0.7)	4.8 (0.8)	4.7 (0.7)	4.9 (0.7)	4.6 (0.6)	4.8 (0.8)
<i>N</i>	75	75	59	59	46	46	69	69
Moderate	4.6 (0.9)	4.7 (1.0)	4.6 (0.8)	4.6 (0.9)	4.9 (0.7)	4.9 (0.6)	4.8 (0.8)	4.9 (0.7)
<i>N</i>	133	133	105	105	98	98	146	146
Severe	4.6 (0.8)	4.6 (0.9)	4.8 (0.8)	4.8 (0.8)	4.7 (0.8)	4.8 (0.8)	4.7 (0.8)	5.0 (0.7)*

Paired ttest for saqli at baseline and at 2 and 6 months stratified by severity and treatment groups

* $P < 0.05$

Table 3: Odds ratios for change in SAQLI >1

	Odds Ratio	95% CI	P value
OSA	0.84	0.4-1.6	0.59
CPAP	1.66	1.1-2.6	0.03*
Compliance	0.86	0.54-1.4	0.53
Obesity	0.79	0.49-1.2	0.23
Depression	0.64	0.33-1.3	0.19
ESS	1.76	1.1-2.7	0.01*
Gender	1.2	0.76-1.9	0.44

Multiple Logistic Regression Model: SAQLI: Sleep Apnea Quality of Life Index, OSA: Obstructive Sleep Apnea, CPAP: Continuous Positive Airway pressure, ESS: Epworth Sleepiness Scale

* $P < 0.05$

Table 4. Change in ESS according to treatment group and stratified by gender

Δ ESS	SHAM			CPAP		
	Mild	Mod	Severe	Mild	Mod	Severe
Males	2.4±3.6	1.7 ±3.3	2.1 ± 3.4	2.9±4.8	1.9 ±4.1	3.1 ±4.5*
Females	2.3 ± 3.4	1.5 ±3.7	2.1 ± 4.1	3.2 ±4.0	3.1 ± 4.3*	3.5 ± 3.9*

ESS: Epworth Sleepiness Scale, * $p < 0.05$

For Peer Review